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Abstract  
Synchrotron-based X-ray fluorescence microscopy, immunofluorescence, and western 
blotting were used to investigate changes in copper (Cu) and Cu-associated pathways in the 
vulnerable substantia nigra (SN) and locus coeruleus (LC), and non-degenerating brain 
regions, in cases of Parkinson’s disease (PD) and appropriate healthy and disease controls. In 
PD and incidental Lewy body disease (ILBD), levels of Cu and Cu transporter protein 1 
(Ctr1), were significantly reduced in surviving neurons in the SN and LC. Specific activity of 
the cuproprotein superoxide dismutase 1 (SOD1) was unchanged in the SN in PD but was 
enhanced in the parkinsonian anterior cingulate cortex (ACC), a region with α-synuclein 
pathology, normal Cu and limited cell loss. These data suggest that regions affected by α-
synuclein pathology may display enhanced vulnerability and cell loss if Cu-dependent 
protective mechanisms are compromised. Further investigation of copper pathology in PD 
may identify novel targets for the development of protective therapies for this disorder.  
 
Keywords: copper; copper transporter 1 (Ctr1); human brain; Parkinson’s disease; substantia 
nigra; superoxide dismutase 1 (SOD1) 
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1. Introduction 
Neurodegenerative cascades in Parkinson’s disease (PD) involve protein aggregation and 
oxidative stress, although the triggers for these events are unknown. Changes in biometals 
have long been suspected to play a role in these cascades. Copper (Cu) is an important 
biometal in the brain, as exemplified by Menkes and Wilson’s diseases; serious neurological 
disorders of Cu dyshomeostasis (de Bie et al., 2007; Schaefer and Gitlin, 1999). A significant 
decrease in total tissue Cu in the degenerating substantia nigra (SN) in PD has been 
consistently reported over a number of decades (Ayton et al., 2012; Dexter et al., 1989; 
Loeffler et al., 1996; Popescu et al., 2009; Uitti et al., 1989) and recent evidence suggests that 
peripheral Cu metabolism is altered in PD (Larner et al., 2013). The complexing of Cu with 
the PD-associated protein ?-synuclein increases aggregation and toxicity of this protein 
(Rose et al., 2011; Wang et al., 2010), possibly via stimulation of free radical production 
(Meloni and Vasak, 2011). On the other hand, Cu is also a critical cofactor in a range of 
cuproproteins, including the key protective cellular antioxidant superoxide dismutase 1 
(SOD1) (McCord and Fridovich, 1969). Studies in model systems demonstrate that Cu 
depletion is associated with reduced activity of SOD1 and a concomitant increase in free 
radical production, which can be normalized by Cu supplementation (Lombardo et al., 2003; 
Prohaska, 1983). SOD1 activity is reduced in the plasma of PD patients (Torsdottir et al., 
2006) and studies in animal models of PD suggest that overexpression of SOD1 increases 
neuronal survival (Battaglia et al., 2002; Botella et al., 2008; Tripanichkul et al., 2007). These 
data suggest that a reduction in brain Cu in PD may reduce SOD1-mediated antioxidant 
defense and contribute to neurodegenerative cascades. In the following work, we investigated 
changes in neuronal Cu levels and transport pathways to determine if changes in Cu are 
associated with a reduced antioxidant capacity in regions of neurodegeneration in PD.  
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2. Methods 
2.1. Brain tissue samples 
Brain tissue samples were requested and received from the New South Wales Tissue Resource 
Centre at the University of Sydney and the Sydney Brain Bank at Neuroscience Research 
Australia. The brain tissue samples were from patients with idiopathic PD and incidental 
Lewy body disease (ILBD), identified according to the diagnostic criteria of Dickson et al. 
(Dickson et al., 2009), and from Alzheimer’s disease (AD) and age-matched controls, 
identified according to the diagnostic criteria of Montine et al. (Montine et al., 2012) 
(Supplementary Tables 1, 2 and 3). All cases of PD had received anti-parkinsonian 
medications prior to death, but none of the ILBD, AD, or control cases had received 
dopamine-replacement therapies. Cases with other neurological or neuropathological 
conditions were excluded and consent to use autopsy material for research purposes was 
obtained for all cases.  
  Brain regions investigated included the SN and locus coeruleus (LC), the brain regions 
most vulnerable to neuronal loss and Lewy body pathology in PD, the anterior cingulate 
cortex (ACC) which is affected by Lewy body pathology later in the course of PD and has 
limited cell loss, and the occipital cortex (OCx), a non-degenerating region in PD (Braak et 
al., 2003; Harding et al., 2002). Samples were collected within 48 hours of death, dissected 
using polytetrafluoroethylene-coated blades (ProSciTech, Queensland, Australia), and the 
fresh tissue samples frozen immediately in liquid nitrogen, then stored at -80°C prior to 
analysis. Fixed tissue samples were stored in formalin prior to cryo-microtome sectioning. 
Due to limited tissue availability, not every brain region was used in every experiment. 
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2.2. Measurement of neuronal and regional Cu levels 
Total Cu levels within cells are the sum of different pools of Cu; free Cu and Cu bound to 
proteins. In the brain the majority of Cu is not free but is tightly regulated by being bound to a 
range of molecules, including Cu transport proteins and other molecules, such as 
neuromelanin (Bohic et al., 2008), an intracellular pigment found in vulnerable regions of the 
PD brain (Hirsch et al., 1988). Total Cu levels were quantified within single neurons as well 
as regions in thin sections (20 µm) cut from fixed or frozen tissue samples using synchrotron 
radiation X-ray fluorescence microscopy (SRXFM) and particle induced X-ray emission 
(PIXE) microscopy. Experiments were conducted using the microprobes endstation at ID22 
beamline of the European Synchrotron Radiation Facility and at the Diamond Light Source 
I18 beamline, as previously described (Antharam et al., 2012; Bohic et al., 2008). Micro-
PIXE and micro-backscattering spectrometry (BS) analyses were performed simultaneously 
using the AIFIRA (Applications Interdisciplinaires des Faisceaux d'Ions en Région Aquitaine) 
facility to enable quantitative chemical analysis of trace elements in cells and tissues 
(Carmona et al., 2008). For each case (Supplementary Table 1) two fixed tissue sections of 
the SN, LC and OCx were investigated: one using SRXFM to raster-scanned individual 
pigmented neurons (6-10 per section/case) with a step size of 1 µm; and the other using PIXE 
microprobes to raster-scan over a 683 μm x 683 μm area, corresponding to the larger scan size 
available for incident protons of 3.0 MeV energy. In the SN and LC, only neurons exhibiting 
normal pigmented morphology were chosen to avoid measurement of extraneuronal 
neuromelanin (NM) pigment. Elemental concentrations derived from single neurons analyzed 
in each section were averaged and only one value from each patient was used in the analysis. 
Results from fixed tissue were confirmed in the SN using the same methods on fresh frozen 
tissue sections from PD and control cases (Supplementary Table 2).  
 For quantification of whole tissue Cu content, samples of fresh frozen brain (35-60 mg) 
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from the SN, ACC and OCx were subjected to closed-vessel microwave digestion (Milestone 
MLS1200) in 4 mL of concentrated nitric acid and 1 mL 35% hydrogen peroxide (both 
Seastar Chemicals, British Columbia, Canada). Digests were diluted w/w to c.a. 50 g with 1% 
nitric acid, and total metal concentrations were determined using an Agilent Technologies 
7500cs inductively coupled plasma mass spectrometer (ICP-MS) (Forrest Hill, Victoria, 
Australia), as previously described (Davies et al., 2013). Specificity for Cu was confirmed by 
measuring both m/z 63 and 65. Cu levels in the SN (subsequently referred to as TH-associated 
Cu levels) were calculated relative to nigral tyrosine hydroxylase determined by Western blot, 
as an index of dopamine neuron loss.  
2.3. Preparation of brain tissue proteins for Western blotting and activity assays 
Samples from fresh frozen brain (62-84 mg) from the SN, ACC and OCx were homogenized 
in 17 volumes of buffer solution (10 mM Tris-HCl, 0.25 M sucrose and 1 mM EDTA, pH 7.4) 
using a hand-held electric homogenizer with a polycarbonate probe (OmniTH, Kelly 
Scientific, Australia). For assaying SOD activity, homogenates of brain tissue proteins were 
centrifuged at 1,500 g for 5 min at 4 °C. For Western blot analysis, 1% SDS and 1:50 dilution 
of protease inhibitor cocktail (Sigma) was added to homogenates of brain tissue proteins 
before being centrifuged at 10,000 g for 15 min at 4 °C. Supernatants were collected and 
stored at -80 °C. Pierce
®
 BCA Protein Assay Kit (Thermo Scientific) was used to determine 
sample protein concentration. 
2.4. Primary antibodies used for detection of Cu transport proteins using Western blotting 
and immunohistochemistry 
Primary antibodies used are detailed in Supplementary Table 4. Specificity of each antibody 
was confirmed by including no primary antibodies and, for Atox1, by preadsorption of the 
Atox1 antibody with the antigen against which the primary antibody was raised (the antigen 
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was not available for the other antibodies used). The ATPase antibodies used in this study 
have been well characterized in previous reports, and their specificity confirmed (Cater et al., 
2007; Ke et al., 2006). Horseradish peroxidase-conjugated antibodies used for detection of 
proteins by Western blotting include: mouse anti-goat IgG, goat anti-mouse IgG, and donkey 
anti-sheep/goat IgG (all Millipore, USA). Fluorescent antibodies used for detection of 
proteins include: donkey anti-goat Alexa Fluor® 594 IgG (H+L), donkey anti-sheep Alexa 
Fluor® 594 IgG (H+L), donkey anti-sheep Alexa Fluor® 488 IgG (H+L), donkey anti-mouse 
Alexa Fluor® 594 IgG (H+L), and donkey anti-rabbit Alexa Fluor® 488 IgG (H+L), all 
purchased from Invitrogen (Eugene, Oregon, USA).  
2.5. SDS-PAGE and Western blot analysis of Cu transport proteins 
The following protein amounts were loaded onto 4-12% Bis-Tris Criterion pre-cast gels (Bio-
Rad); Copper transporter 1 (Ctr1): 40 mg, Atox1: 80 mg, ATP7A: 100 mg, ATP7B: 100 mg, 
SOD1: 2.5 mg, Tyrosine Hydroxylase (TH): 40 mg, and separated by SDS-PAGE in MES 
(Atox1) or MOPS (Ctr1, ATP7A, ATP7B, SOD1, TH) buffer (Bio-Rad), according to 
manufacturer’s instructions (Bio-Rad). Separated proteins were transferred to Immobilon- P
SQ
 
PVDF (Millipore) (Ctr1, Atox1, SOD1, and TH) or nitrocellulose (Millipore) (ATP7A and 
ATP7B) membranes. Following transfer, membranes were blocked in either 5% skim milk  
(Ctr1, ATP7A, ATP7B, SOD1, and TH), or 1% casein (Atox1), in PBS containing 0.1% 
Tween
®
 20
 
and incubated with appropriate primary antibodies diluted in PBS containing 0.1% 
Tween
®
 20 and 1% skim milk (Ctr1, ATP7A, ATP7B, SOD1, and TH) or 1% casein (Atox1) 
at the following concentrations: Ctr1 (1:200), Atox1 (1:250), ATP7A (1:750), ATP7B 
(1:1500), SOD1 (1:10,000), and TH (1:5000) overnight at 4 °C. Following incubation with 
horseradish peroxidase-conjugated mouse anti-goat IgG (1:10,000), goat anti-mouse IgG 
(1:2,000), donkey anti-sheep/goat IgG (1:2,000), or donkey anti-rabbit IgG (1:5000), protein 
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signals were obtained using an ECL Western blotting detection system (Bio-Rad) as per the 
manufacturer’s instructions, and developed using the Chemi-Doc XRS (Bio-Rad). Signal 
intensities were quantified by densitometry using Quantity One® software (Bio-Rad) and 
normalized to ?–actin (1:10,000) levels. TH levels in the SN were quantified by Western 
blot to provide an indication of dopaminergic cell loss. As expected, TH levels in the PD SN 
were significantly reduced by 60% (p=0.013). Levels of the Cu transporters Ctr1 
(subsequently referred to as TH-associated Ctr1 levels), Atox1, ATP7A, and ATP7B were 
calculated relative to TH levels in the SN.  
2.6. Cu transport protein immunohistochemistry 
Formalin fixed slide-mounted paraffin-embedded sections (7µm) were antigen retrieved by 
either incubation with Tris-EDTA buffer (0.01M Tris, 1 mM EDTA, pH 9.0) at 95 °C for 20 
mins (Ctr1), or by microwave irradiation in citrate buffer (pH 6.0) for 15 mins (ATP7A and 
ATP7B). Non-specific peroxidases were blocked with 1% H2O2 (Fronine Laboratory 
Supplies) in 50% ethanol for 30 mins at room temperature. Non-specific antigen sites were 
blocked with a mixture of 1% bovine serum albumin (BSA; Sigma) and 5% normal horse 
serum (NHS; Australis) (Ctr1), Animal Free Blocker™ (Vector Laboratories) (ATP7A), or 
3% BSA (Sigma) (ATP7B), for 20 mins at room temperature. Primary antibodies for 
immunohistochemistry were used at the following dilutions: Ctr1 (1:100), ATP7A (1:300), 
ATP7B (1:1,000). Primary antibodies for Ctr1, ATP7A and ATP7B were detected using 
biotinylated IgG antibodies (Vector Laboratories) (1:200), followed by Vector Elite Kit 
tertiary antibody complex (Vector Laboratories) (1:100), and visualized using 3’3’-
diaminobenzidine (DAB; Sigma) with a cresyl violet counterstain (Sigma). Images were taken 
using a Zeiss AxioCam HRc microscope.  
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2.7. Cu transport protein immunofluorescence 
Due to the inherent difficulty of separating positive DAB staining from NM, 
immunofluorescence staining was performed on midbrain and pons tissue sections to examine 
the cellular localization of Ctr1, ATP7A, and ATP7B in SN and LC neurons. Formalin fixed 
free-floating midbrain sections (50 µm; Ctr1; Supplementary Table 3), formalin fixed slide-
mounted sections (20 µm; Ctr1; Supplementary Table 1), and formalin fixed slide-mounted 
paraffin-embedded sections (7 µm; ATP7A, ATP7B; Supplementary Table 3) were antigen 
retrieved in Tris-EDTA buffer (0.01 M Tris, 1 mM EDTA, pH 9.0) at 95 °C for 25 mins 
(Ctr1), or citrate buffer (pH 6.0) with microwave irradiation for 15 mins (ATP7A, ATP7B), 
and permeabilized with 50% ethanol. Non-specific antigen sites were blocked in 10% NHS 
(Australis; Ctr1), or 0.25% Casein (Sigma; ATP7A, ATP7B) for 1 hour at room temperature 
and midbrain sections double-stained for the dopaminergic cell marker tyrosine hydroxylase 
(TH; 1:500) and for Ctr1 (1:25), ATP7A (1:100), or ATP7B (1:400). Primary antibodies were 
detected using secondary IgG antibodies conjugated to Alexa Fluor® 594 or Alexa Fluor® 
488 fluorophores (Invitrogen). Sections were analysed using a Nikon D-Eclipse C1 Si 
scanning confocal microscope. The cross-reactivity and specificity of the fluorescence 
reactions were tested by incubating each primary antibody singularly with the secondary 
antibody solution containing two fluorophores. No cross reactivity was observed.  
2.8. SOD1 Activity Assay 
SOD activity was determined using SOD determination kit (Sigma, Cat. #19160) according to 
the manufacturer’s instructions. Total SOD activity was measured in supernatants, and SOD2 
activity was measured by the addition of 5 mM potassium cyanide (Sigma). SOD1 activity 
(units/μg protein) was measured as the difference between total SOD, and SOD2, activity. 
The specific activity of SOD1 was determined by normalizing SOD1 activity (units/μg 
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protein) to SOD1 protein levels. A single PD case was excluded from analysis due to a 
medication history of selegiline, demonstrated to increase midbrain SOD1 activity (Takahata 
et al., 2006). 
2.9. Statistical Analyses 
Statistical analyses were performed using PASW v18 (SPSS inc.). Univariate analysis of 
variance followed by Bonferroni’s t-test was used to test for differences between groups. 
Linear regression was used to test for relationships between variables. A p-value of less than 
0.05 was accepted as the level of significance. 
 
3. Results 
3.1. Decreased Cu precedes regional cell loss in PD  
Quantitative analysis of fixed sections by SRXFM (Fig 1A-C) revealed a decrease in NM-
associated Cu in the SN from PD and ILBD cases with respect to both age-matched controls 
(45% decrease in PD, p<0.0001 and 48% decrease in ILBD, p=0.0003) and AD cases (31% 
decrease in PD, p=0.003 and 34.5% decrease in ILBD, p=0.007) (Fig 1A). Our finding of 
decreased NM-associated Cu levels in the PD SN was confirmed in fresh frozen tissue 
sections (65%, p<0.0001; Fig 2). A representative set of selected SRXFM elemental images 
from typical NM-containing neurons is shown in Fig 2. SRXFM imaging of single pigmented 
neurons demonstrated that Cu was colocalized with NM and that there was no change in the 
spatial distribution of Cu between control and PD cases.  Similarly, analysis of NM from LC 
neurons showed a 55% decrease in Cu content in PD compared with controls (p=0.001; Fig 
1B) while no differences were seen in the grey matter of the OCx (Fig 1C). This data 
confirms a specific reduction in Cu within remaining NM-pigmented neurons in PD and 
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shows that this deficit occurs in cases with ILBD and limited cell loss, suggesting an early 
deficit that precedes cell death and clinical symptoms. 
 Complementary to SRXFM, we quantified intraneuronal Cu levels in separate tissue 
sections using micro-PIXE to assess Cu content in randomly sampled regions (683 mm x 683 
mm) of the SN, LC, and OCx (Fig 1D-F). Alignment of the carbon map and optical 
microscopic view allowed independent quantification of melanized and non-melanized tissue 
within each region. Elemental concentrations obtained using micro-PIXE were within the 
range of those obtained using SRXFM. Micro-PIXE analysis of NM-containing neurons 
confirmed a decrease in Cu-associated NM in PD (54%, p=0.0012) and ILBD (60%, p=0.004) 
compared with controls (Fig 1D). Importantly, the Cu decrease was also observed in NM 
from neurons of the LC (Fig 1E) but not in the OCx (Fig 1F).  
 Quantification of iron (Fe) and zinc (Zn) levels by PIXE revealed a 49% increase in Fe 
(p<0.05) in NM-containing neurons in fresh frozen PD SN compared with fresh frozen 
control SN, while Zn concentrations were similar between PD and control cases 
(Supplementary Table 5). These findings were confirmed by SRXFM on an adjacent set of 
sections (26% increase in Fe, p< 0.05, Supplementary Table 6). In contrast, Fe levels were not 
altered in fixed tissue within multiple individual pigmented neurons, suggesting that chemical 
fixation masks changes in Fe in PD. No other changes were found for NM-associated 
elements investigated across the disease groups in either the SN or LC. 
3.2. Reduced Ctr1 is an early change in regions of cell loss in PD 
TH-associated Ctr1 was significantly reduced in the SN of the PD brain (50% reduction in 
Ctr1, p=0.017, Fig 3A) and was significantly correlated with TH-associated Cu levels 
(p=0.036; Fig 3B) and disease duration (p=0.008; Fig 3C). We have previously described in 
the normal SN (Davies et al., 2013) robust Ctr1 staining localized with NM (Fig 4A). In the 
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PD SN however, consistent with our Western blot data, NM-associated Ctr1 
immunoreactivity was markedly reduced (Fig 4B). Interestingly, this was restricted to SN 
dopaminergic neurons, as robust Ctr1 NM staining was observed in pigmented neurons in the 
nearby ventral tegmental area (VTA) and retrorubral field (Fig 4B, inset). NM-associated Ctr1 
immunoreactivity in the SN of AD cases was equivalent to that in control cases (Fig 4C), in 
contrast, a marked reduction in NM-associated Ctr1 immunoreactivity was observed in the 
majority of SN neurons in cases of ILBD (Fig 4D).  
 NM-associated Ctr1 staining in the control LC was more variable compared to the 
consistently robust staining observed in the control SN. However, while neurons strongly 
expressing Ctr1 were frequently observed in control (Fig 4E) and AD cases (Fig 4G), strong 
Ctr1 immunoreactivity was rarely observed in the PD (Fig 4F) and ILBD LC (Fig 4H).  
 We have previously described strong cytoplasmic expression of Ctr1 in neuronal cell 
bodies in the normal ACC (Davies et al., 2013) (Fig 5A). Interestingly, in contrast to the PD 
SN and LC, strong cytoplasmic expression of Ctr1 was preserved in the ACC in PD (Fig 5B), 
consistent with our Western blot data in this brain region (Fig 5C). Immunoreactivity for 
ATP7A, ATP7B, and Atox1 in SN and ACC did not differ between PD and control cases. 
3.3. Increased SOD1 levels relates to reduced Cu levels in regions of cell loss in PD 
SOD1 levels and specific activity were not associated with age, PM delay, or tissue pH. 
Consistent with our previous findings (Davies et al., 2013), in the control brain Cu levels were 
significantly higher in the SN compared with those in the OCx and ACC (p=0.001, p≤0.001, 
respectively). Confirming the decrease in SN Cu at the neuronal level, total tissue Cu was 
reduced by 48% in the PD SN compared with control (p=0.032). Regional protein levels of 
SOD1 in the control SN, OCx, and ACC did not vary significantly, and were not correlated 
with Cu levels; in contrast in the PD SN there was significantly more SOD1 compared with 
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the OCx and ACC (p=0.002, p=0.007, respectively; Fig 6A and B) and SOD1 levels were 
correlated with Cu levels (p=0.004; Fig 6C).  
3.4. Initial enhancement of SOD1 antioxidant activity in regions affected by late PD 
pathology 
Specific activity of SOD1 did not vary between the regions studied in the control brains 
(p=1.000; Fig 7), but in contrast, in the PD brains SOD1 specific activity was significantly 
greater in the ACC compared with the SN (p=0.032; Fig 7), and there was a trend for 
increased SOD1 specific activity in the parkinsonian ACC compared with the control ACC 
(p=0.076; Fig 7).  
 
4. Discussion  
The current data demonstrate that Cu, and the expression of the Cu transport protein Ctr1, are 
decreased within the intraneuronal environment of surviving dopaminergic neurons of the SN 
and LC in ILBD and PD (Fig 1, 2, 3, and 4). As ILBD is suggested to represent preclinical PD 
(Dickson et al., 2009) and these cases had not taken anti-parkinsonian medications, this 
suggests these changes occur early in the disease process and are independent of treatment. As 
Cu and Ctr1 levels were not altered in the degenerating LC in AD, it is unlikely that the 
reduction in Cu and Ctr1 observed in these regions in PD results simply from 
neurodegeneration per se. Further, as Cu and Ctr1 levels were unchanged in regions that do 
not degenerate in PD, it appears that this early decrease is specific to regions vulnerable to 
neuronal cell loss in this disorder.  
 Our data in the PD brain show an association between decreasing Ctr1 and Cu levels 
selectively in regions degenerating in PD (Fig 4), with the decrease in Ctr1 in PD enhanced in 
patients with longer disease durations and greater cell loss (Fig 3). Data from animal models 
in
se
rm
-0
09
68
92
3,
 v
er
sio
n 
1 
- 1
 A
pr
 2
01
4
  
15 
show that a decrease in Ctr1 leads to significant neuronal dysfunction and death. Deletion of 
Ctr1 is embryonic lethal and epithelial cell-specific Ctr1 knockout mice display neonatal 
defects and severe growth and viability abnormalities (Nose et al., 2006). In addition, 
organisms lacking Ctr1 are deficient in oxidative stress protection (Dancis et al., 1994; De 
Freitas et al., 2000; Knight et al., 1996). While our data demonstrate a change in Ctr1 in the 
parkinsonian brain, the regulation of intracellular Cu is complex and other yet to be 
characterized Cu transport pathways may also be altered in PD. It has recently been shown, 
for example, that down-regulation of Ctr1 in a murine model of Wilson’s disease is linked to 
the appearance of a redundant mechanism of Cu transport, the 2 kDa Small Copper Carrier, 
SCC (Gray et al., 2012). A second Ctr protein, structurally related to Ctr1, has also been 
identified in mammals, designated Copper transporter 2 (Ctr2). This protein has not been 
identified in human tissue but is thought to play a role in low affinity Cu import (Bertinato et 
al., 2008) and in intracellular Cu mobilization (Rees and Thiele, 2007). 
 To determine the functional consequences of reduced intraneuronal Cu, we assessed a 
key antioxidant cuproprotein in the brain, SOD1, and identified an associated increase in 
levels of SOD1 protein in the degenerating PD SN (Fig 6A and B). The relationship we 
observed between Cu and SOD1 levels is consistent with the hypothesis that cellular Cu 
levels regulate SOD1 expression (Brown et al., 2004; Henchcliffe and Beal, 2008). Despite 
this increase in SOD1 protein levels, specific activity of SOD1 was unchanged in the PD SN 
(Fig 7). In contrast, in the ACC, where Cu and Ctr1 levels are normal SOD1 specific activity 
was increased above that in the SN of the same brains (Fig 7) and there was a trend for SOD1 
specific activity to be higher in the parkinsonian, compared with the control ACC (Fig 7). The 
increased SOD1 specific activity observed in the ACC where Cu levels are normal, but not in 
the Cu-deficient SN, suggests that a lack of Cu bioavailability may compromise the function 
of cuproproteins, such as SOD1. In support of this hypothesis, a profound decrease in the 
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specific activity of another cuproprotein, ceruloplasmin, was recently reported in the SN in 
PD (Ayton et al., 2012), a finding with likely implications for iron accumulation and 
subsequent oxidative stress in PD.   
 Genetic alterations causing dysfunctional Cu transport proteins and reduced brain Cu 
levels result in severe neurodegeneration, as observed in Menkes disease (Kaler, 2011; 
Strausak et al., 2001). The current understanding of neuronal death in PD supports a role for 
?-synuclein and oxidative stress in these degenerative pathways.  We have previously shown 
that the earliest deposition of ?-synuclein in the parkinsonian SN occurs on NM (Halliday et 
al., 2005) and both regional and NM-associated Cu levels are significantly higher in the 
normal SN and LC compared with other brain regions (Bohic et al., 2008; Davies et al., 
2013). High Cu levels promote the formation of oligomeric (toxic) forms of α-synuclein 
(Binolfi et al., 2010; Rose et al., 2011; Santner and Uversky, 2010; Wright et al., 2009). Our 
current data suggest that the presence of Cu associated with NM in these most vulnerable 
neurons may underlie the greater propensity of ?-synuclein to abnormally accumulate in 
pigmented catecholaminergic neurons, compared with non-pigmented brain regions, such as 
the ACC. Further studies are required to understand the relationships between NM, Cu and α-
synuclein and their roles in neuronal death in the parkinsonian brain.  
 Our data demonstrate decreased cellular copper levels and disrupted copper pathways in 
vulnerable brain regions in PD, as well regional changes in SOD1 specific activity that reflect 
the pattern of neurodegeneration in PD. We also show that neuronal SOD1 protein levels are 
increased in association with a decrease in Ctr1 and Cu levels prior to cell loss in regions most 
vulnerable to PD-associated neurodegeneration. These changes are enhanced with increasing 
disease duration. The reduced activity of copper-dependent SOD1 shown here, and that of 
ceruloplasmin (Ayton et al., 2012), suggests that a reduction in cellular Cu compromises the 
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ability of these neurons to defend themselves against oxidative stress, consistent with the 
severity of cell loss observed in these vulnerable regions in the PD brain.  
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Figure legends 
 
Figure 1. Intraneuronal copper (Cu) levels measured in fixed brain tissue by Synchrotron X-
ray fluorescence microscopy (A-C) and particle induced X-ray emission (PIXE) microprobes 
(D-F). Intraneuronal Cu levels were significantly reduced in the Parkinson’s disease 
(Parkinson) and Incidental Lewy Body disease (ILBD) substantia nigra (SN), compared to 
control (Normal), but remained unchanged in the Alzheimer’s disease (AD) SN (A, D).  
Intraneuronal Cu levels were significantly reduced in the Parkinson’s locus coeruleus (LC), 
compared to control (B, E), while Cu levels remained unchanged in the Parkinson’s and AD 
occipital cortex (OCx) (C, F). Bars are mean ± SEM. The numbers of samples analyzed by 
PIXE and/or Synchrotron X-ray fluorescence microscopy are reported in Supplementary 
Table 5 and 6, respectively. Significant differences were determined by multivariate analysis 
of variance (ANOVA), p<0.05. 
 
Figure 2. Representative map for copper (Cu) obtained from single intact neuromelanin-
containing neurons in the substantia nigra (SN) of a Parkinson’s disease (Parkinson, n=5) and 
control (Normal, n=5) case, by Synchrotron X-ray fluorescence microscopy (A, B). The X-ray 
fluorescence signal intensity is shown as a color scale. Intraneuronal Cu levels, measured in 
fresh frozen tissue sections, were significantly reduced in the Parkinson’s disease SN 
compared to normal controls (C). Bars in (C) are mean ± SEM. Significant differences 
between normal and Parkinson’s brains* were determined by two-tailed t-test, p<0.05. 
 
Figure 3. Tyrosine hydroxylase (TH)-associated Copper transporter 1 (Ctr1) levels in the 
substantia nigra in Parkinson’s disease (Parkinson) (n=7) were significantly reduced 
compared with controls (Normal) (n=6) (A) and were positively correlated with TH-
associated copper (Cu) levels (B) and disease duration (C). Ctr1 and TH levels were 
in
se
rm
-0
09
68
92
3,
 v
er
sio
n 
1 
- 1
 A
pr
 2
01
4
  
23 
quantified by densitometry performed on Western blots and normalized to β-actin levels (used 
as a loading control). Cu levels were determined by inductively coupled plasma-mass 
spectrometry and calculated relative to TH levels. Bars in (A) are mean ± SEM. Significant 
differences between normal and Parkinson’s brains* were determined by Univariate analysis 
of variance followed by Bonferroni-corrected posthoc t-tests. 
 
Figure 4. Representative photomicrographs of Copper transporter 1 (Ctr1) in the control 
(Normal) (A, E), Parkinson’s disease (B, F), Alzheimer’s disease (AD) (C, G), and Incidental 
Lewy Body disease (ILBD) (D, H) substantia nigra pars compacta dopaminergic neurons (A-
D) and locus coeruleus noradrenergic neurons (E-H). Midbrain and pons sections were dual 
stained for dopaminergic marker, tyrosine hydroxylase (TH; green), and Ctr1 (red). Insets: no 
Ctr1 primary control (A) and Parkinson’s disease (B) neurons from the ventral tegmental area 
positively stained for Ctr1.  
 
Figure 5. The cellular localization (A-B) and levels (C) of the copper transport protein 
Copper transporter 1 (Ctr1) in the anterior cingulate cortex (ACC) of the normal control (n=7) 
(A) and Parkinson’s disease (n=6) (B) brain. Cellular localization was investigated on 7μm 
paraffin embedded sections probed for Ctr1 using peroxidase immunohistochemistry (brown) 
with cresyl violet counterstain. Regions of positive staining are dark brown. Scale bar in B 
applies to A and B. Ctr1 levels (C) were quantified by densitometry performed on Western 
blots and normalized to β-actin levels (used as a loading control). Values are mean ± SEM. 
Differences between normal and Parkinson’s brains were determined by Univariate analysis 
of variance followed by Bonferroni-corrected posthoc t-tests. 
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Figure 6. Superoxide dismutase 1 (SOD1) levels in the substantia nigra (SN), anterior 
cingulate cortex (ACC) and occipital cortex (OCx) of the normal and Parkinson’s disease 
brain (A). SOD1 levels were quantified by densitometry performed on Western blots and 
normalized to β-actin levels (used as a loading control) (B). Values are mean ± SEM. 
Significant differences between regions in normal and Parkinson’s brains, determined by 
Univariate analysis of variance followed by Bonferroni-corrected posthoc t-tests, are 
indicated*. Normal SN, n=8; ACC, n=8; and OCx, n=8. PD SN, n=7; ACC, n=7; and OCx, 
n=7. SOD1 levels were significantly associated with copper (Cu) levels in the Parkinson’s 
disease brain, but not in normal controls (C). Cu levels were determined by inductively 
coupled plasma-mass spectrometry. 
 
 Figure 7. Superoxide dismutase 1 (SOD1) specific activity in the substantia nigra (SN), 
anterior cingulate cortex (ACC), and occipital cortex (OCx) of the normal and Parkinson’s 
disease brain. SOD1 specific activity was not significantly different between brain regions in 
control cases (Normal), but was significantly disrupted in the Parkinson’s disease brain in 
regions affected by α-synuclein pathology (SN and ACC), in a manner that reflected cellular 
vulnerability (p=0.032*). There was a strong trend (p=0.076) for SOD1 specific activity in the 
PD ACC to be greater than that in the control ACC. Values are mean ± SEM. Differences 
between brain regions within diagnostic groups and between normal and Parkinson’s brains 
were determined by Univariate analysis of variance followed by Bonferroni-corrected posthoc 
t-tests. Normal SN, n=8; ACC, n=8; and OCx, n=8. PD SN, n=6; ACC, n=7; and OCx, n=6. 
SOD1 specific activity was determined by normalizing SOD1 activity (units/μg protein) to 
SOD1 protein levels. 
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Figure 2 
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Figure 3 
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Supplementary Information 
Supplementary Table 1 
Subject 
Demographics 
Control 
subjects 
(N=10) 
PD 
Patients  
(N=10) 
ILBD 
Patients 
(N=3) 
AD 
Patients 
(N=6) 
Sex f/m 7/3 7/3 0/3 4/2 
Age (years)  
(range) 
82.4±10.2 
(69-98) 
77.6±8.7 
(69-92) 
79±10.1 
(68-88) 
78.3±6.8 
(74-88) 
pmd (hrs) 25.6±13.5 21.9±9.1 55.3±27.2 17.8±15.8 
Tissue pH (range) 7.2 – 7.4 7.2 – 7.4 7.2 – 7.4 7.2 – 7.4 
Time in fixative 
(years) 
2.4±1.2 2.8±1.5 2.8±0.3 3.0±0.9 
DD (years) – 12.7±4.3 – 9.5±4.6 
H/Y stage – 
5 patients stage 5 
– DD 5-16 y 
3 patients stage 4 
– DD 10-20 y 
1 patient stage 3 
– DD 13 y 
1 patient stage 2 
– DD 6 y 
– – 
Duration of L-dopa 
treatment (years) 
– 11.5±4 – – 
 
Tissue characteristics and clinical data for formalin fixed samples studied using synchrotron 
X-ray fluorescence and PIXE microprobes to measure cellular copper levels, and for 
immunofluorescence studies of cuproprotein localization. Regions investigated include the 
substantia nigra, locus coeuruleus, and occipital cortex. Values are presented as mean ± SD 
and/or range. PD = Parkinson’s disease, ILBD = Incidental Lewy Body Disease, AD = 
Alzheimer’s disease, f = female, m = male, pmd = Post-mortem delay, DD = Disease 
duration, H/Y stage = Hoehn and Yahr stage. 
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Supplementary Table 2 
Subject 
Demographics 
Control 
subjects 
(N=5) 
PD 
Patients  
(N=5) 
Sex f/m 1/4 1/4 
Age (years)  
(range) 
82.4±6.0 
(73-88) 
80.6±6.3 
(73-90) 
pmd (hrs) 21.7±16.1 21.9±9.1 
Tissue pH (range) 6.28 –6.75 6.25 –6.69 
Storage time in 
freezer (years) 
2.9±1.1 3.0±1.2 
DD (years) – 16.6±3.9 
H/Y stage – 
3 patients stage 5 
– DD 13-15 y 
2 patients stage 4 
– DD 17,24 y 
 
 
Tissue characteristics and clinical data for fresh frozen samples studied using synchrotron X-
ray fluorescence and PIXE microprobes to determine cellular copper levels in the substantia 
nigra. Values are presented as mean ± SD and/or range. PD = Parkinson’s disease, f = female, 
m = male, pmd = Post-mortem delay, DD = Disease duration, H/Y stage = Hoehn and Yahr 
stage. 
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Supplementary Table 3 
 Fresh frozen Fixed 
Subject 
Demographics 
Control 
subjects 
(N=8) 
PD 
Patients 
(N=7) 
Control 
subjects 
(N=3) 
PD 
Patients 
(N=3) 
Sex f/m 2/6 2/5 1/2 1/2 
Age (years)  
(range) 
69±28 
(41-103) 
80±7 
(69-90) 
93±10 
(84-103) 
78±4 
(74-82) 
pmd (hrs) 23±6.9 12±7.6 24±20.3 32±13.7 
Tissue pH 5.9 – 7.0 5.9 – 6.8 6.1 – 6.7 5.9 – 7.0 
DD (years) – 11.7±4.3 – 7.3±0.6 
H/Y stage – 
1 patient 
stage 6 – DD 
8 yrs 
6 patients 
stage 5 – DD 
5-17 yrs 
 
– 
3 patients 
stage 6 – DD 
7-8 yrs 
 
 
Case details for tissues investigated for cuproprotein levels (fresh frozen) and cellular 
localization (fixed), and SOD1 activity (fresh frozen). Regions investigated include the 
substantia nigra, anterior cingulate, and occipital cortices. Tissue characteristics and clinical 
data presented as mean +/- SD and (range). PD = Parkinson’s disease, ILBD = Incidental 
Lewy Body Disease, AD = Alzheimer’s disease, f = female, m = male, pmd = Post-mortem 
delay, DD = Disease duration, H/Y stage = Hoehn and Yahr stage. 
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Supplementary Table 4 
Antigen Immunogen Source 
Ctr1 Peptide mapping within amino 
acids 100-150 of CTR1 of human 
origin. 
Santa Cruz Biotechnology, Inc. 
(CA, USA); CTR1 (G-15); goat 
polyclonal. 
Atox1 ATOX1 (NP_004036, 1 a.a. – 
68a.a.) partial recombinant protein 
with GST tag. 
Abnova (Taiwan); ATOX1, clone 
2E6; mouse monoclonal. 
ATP7A First 590 N-terminal amino acids 
of the human MNK protein. 
In-house original antibody; R17; 
sheep polyclonal (Ke et al., 2006). 
ATP7B 36-kDa fusion protein with a His6 
tag at the N-terminus of the 
protein comprising amino acids 1-
199 (N-terminal), 1309-1315 and 
1376-1465 (C-terminal) of the 
human ATP7B protein. 
In-house original antibody; NC36; 
sheep polyclonal (Cater et al., 
2007). 
SOD1 Highly purified, human erythrocyte 
SOD Cu/Zn. 
Chemicon (Millipore) (Billerica, 
MA, USA); Anti-Superoxide 
Dismutase (Cu/Zn Enzyme); 
sheep polyclonal. 
β-actin Amino acids 50-70 of purified 
chicken gizzard actin. 
Millipore (Billerica, MA, USA); 
Anti-Actin, clone C4; mouse 
monoclonal 
TH (IF) Amino acids 1-196 of TH of 
human origin. 
Santa Cruz Biotechnology, Inc. 
(CA, USA); TH (H-196); rabbit 
polyclonal. 
TH (WB) Denatured tyrosine hydroxylase 
from rat pheochromocytoma. 
Chemicon (Millipore) (Billerica, 
MA, USA); Anti-Tyrosine 
Hydroxylase Antibody; rabbit 
polyclonal. 
 
Primary antibodies. 
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Supplementary Table 5  
Brain regions   Fe Cu Zn 
Occipital 
cortex 
 
Normal 
(N=4) 
225 
(24) 
36 
(10) 
83 
(32) 
PD 
(N=4) 
188 
(36) 
27 
(9) 
78 
(24) 
AD 
(N=3) 
 
261 
(48) 
 
22 
(7) 
79 
(32) 
SN tissue 
 
Normal 
(N=8) 
699 
(388) 
81 
(23) 
147 
(60) 
PD 
(N=7) 
500 
(266) 
36 
(9)  
86 
(37) 
ILBD 
(N=2) 
708 
 (136) 
42 
 (27) 
177 
(76)  
AD 
(N=6) 
 814 
(197) 
88 
(16)  
193 
 (63) 
SN 
Neuromelanin 
 
Normal 
(N=8) 
1799 
(771) 
104 
(27) 
196 
(65) 
PD 
(N=7) 
924 
(229) 
48 
(25) 
102 
(38) 
ILBD 
(N=2) 
 1306 
(277) 
41 
(14)  
201 
(88) 
AD 
(N=6)  
1668 
(574)  
122 
(55)  
321 
  (29) 
 
 Normal frozen 
(N=5) 
1105 
(347) 
126 
(38) 
153 
(24) 
 PD frozen 
(N=5) 
1646 
(353) 
44 
(23) 
128 
(33) 
LC 
Neuromelanin 
 
Normal 
(N=4) 
588 
(114) 
83 
(10) 
107 
(21) 
 
PD 
(N=4) 
759 
(258) 
34 
(8) 
111 
(24) 
 
 
Iron (Fe), copper (Cu) and zinc (Zn) concentrations, determined by Particle-Induced X-Ray 
Emission (PIXE), in the occipital cortex, substantia nigra pars compacta (SN), and within 
neuromelanin (NM) of neurons from the substantia nigra pars compacta (SN) and locus 
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coeruleus (LC) of Parkinson’s disease (PD), Incidental Lewy Body Disease (ILBD) and 
Alzheimer’s disease (AD) patients, compared with normal controls. All tissues were 
chemically fixed, unless otherwise stated, in which case fresh frozen sections were analysed. 
Data reported as mean elemental concentrations, expressed as mg/g dry weight, with standard 
deviations reported in parentheses. 
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Supplementary Table 6:  
Brain regions   Fe Cu Zn 
Occipital 
cortex 
 
Normal 
(N=4) 
222.5 
(13) 
23 
(5) 
94 
(7) 
PD 
(N=4) 
209 
(7.5) 
26 
(2) 
84 
(17) 
AD 
(N=3) 
 
227 
(14) 
20.5 
(6) 
92 
(9) 
SN 
Neuromelanin 
 
Normal 
(N=10) 
2135 
(805) 
69 
(14) 
206 
(55) 
PD 
(N=10) 
1910 
(709) 
38 
(6) 
196 
(63) 
ILBD 
(N=3) 
796 
(146) 
36 
(5) 
112 
(26) 
AD 
(N=5)  
1685 
(290) 
55 
(4) 
238 
(90) 
 Normal frozen 
(N=5) 
1267 
(229) 
81 
(10) 
154 
(38) 
 PD frozen 
(N=5) 
1594 
(187) 
29 
(6) 
134 
(25) 
LC 
Neuromelanin 
 
Normal 
(N=5) 
826 
(225) 
69 
(11) 
153 
(43) 
PD 
(N=5) 
1086 
(397) 
31 
(13) 
186 
(43) 
 
Iron (Fe), copper (Cu) and zinc (Zn) concentrations, determined by synchrotron X-ray 
fluorescence microscopy, in the occipital cortex and within neuromelanin (NM) of neurons 
from the substantia nigra pars compacta (SN) and locus coeruleus (LC) of Parkinson’s disease 
(PD), Incidental Lewy Body Disease (ILBD) and Alzheimer’s disease (AD) patients, 
compared with normal controls. All tissues were chemically fixed, unless otherwise stated, in 
which case fresh frozen sections were analysed. Data reported as mean elemental 
concentrations, expressed as mg/g dry weight, with standard deviations reported in 
parentheses.  
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Supplementary Figure 1: Representative map for sulfur (S), iron (Fe), copper (Cu), zinc 
(Zn) and selenium (Se) obtained from single intact neuromelanin-containing neurons in the 
substantia nigra (SN) of healthy normal (a and b), Parkinson’s disease (c and d), Incidental 
Lewy body disease (e), and Alzheimer’s disease (f) cases, by Synchrotron X-ray fluorescence 
microscopy. a) and d) are from human fresh frozen SN while all other images are from 
chemically fixed human SN. The X-ray fluorescence signal intensity is shown as a color scale 
and allows for the comparison of each elemental map for the different cases. Scale bars, 10 
µm. 
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Supplementary Figure 2: Representative map for sulfur (S), iron (Fe), copper (Cu), zinc 
(Zn) and selenium (Se) obtained from single intact neuromelanin-containing neurons in the 
locus coeruleus (LC) of a healthy normal (a) and Parkinson’s disease (PD) (b) case, by 
Synchrotron X-ray fluorescence microscopy. All tissues are from chemically fixed human LC. 
The X-ray fluorescence signal intensity is shown as a color scale and allows for the 
comparison of each elemental map for healthy normal and PD cases. Scale bars, 10 µm. 
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